Moderna reports five-year melanoma trial results with Merck and expands its Ebola vaccine partnership with CEPI, but MRNA stock is down.
Moderna, Inc.
(NASDAQ:MRNA) stock is trading lower on Monday.
The COVID-19 vaccine maker and Merck & Co Inc.
(NYSE:MRK) reported five-year follow-up results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of individualized neoantigen therapy intismeran autogene (mRNA-4157/V940) plus KEYTRUDA for high-risk stage III/IV melanoma after complete surgical resection. • Moderna stock is under selling pressure.
What's driving MRNA stock lower?
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
Moderna partners with CEPI on Bundibugyo Ebola vaccine
Moderna and other groups get $60 million to develop Ebola vaccine - The Korea Times
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
A personalized vaccine for melanoma cut the risk of cancer returning after five years
Közel 60 százalékkal csökkentette a melanóma áttétképződésének kockázatát egy kísérleti vakcina
A cancer vaccine made just for you. mRNA is back and it's fighting melanoma
Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo
mRNA-Impfung gegen Krebs: Steht der Durchbruch bevor?
Analysts pointed to an upcoming health care conference and cancer data study release as potential catalysts for Moderna's ongoing…
The vaccines are tailor-made to target each patient's unique cancer.
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in…
Coalition for Epidemic Preparedness Innovationsfunding builds on Moderna's prior filovirus research and supports preclinical…
CEPI is committing up to $50 million to support Moderna's vaccine candidate for the strain with no approved shot
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
